IL155278A0 - Pyridinone derivatives for treatment of atherosclerosis - Google Patents

Pyridinone derivatives for treatment of atherosclerosis

Info

Publication number
IL155278A0
IL155278A0 IL15527801A IL15527801A IL155278A0 IL 155278 A0 IL155278 A0 IL 155278A0 IL 15527801 A IL15527801 A IL 15527801A IL 15527801 A IL15527801 A IL 15527801A IL 155278 A0 IL155278 A0 IL 155278A0
Authority
IL
Israel
Prior art keywords
atherosclerosis
treatment
pyridinone derivatives
pyridinone
derivatives
Prior art date
Application number
IL15527801A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL155278A0 publication Critical patent/IL155278A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15527801A 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis IL155278A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024808.8A GB0024808D0 (en) 2000-10-10 2000-10-10 Novel compounds
PCT/EP2001/011610 WO2002030904A1 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
IL155278A0 true IL155278A0 (en) 2003-11-23

Family

ID=9901006

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15527801A IL155278A0 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis
IL155278A IL155278A (en) 2000-10-10 2003-04-08 Compressed Pyridine-4-On and Pyridine-4-On Derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155278A IL155278A (en) 2000-10-10 2003-04-08 Compressed Pyridine-4-On and Pyridine-4-On Derivatives

Country Status (28)

Country Link
US (2) US20040063753A1 (de)
EP (2) EP2258688B1 (de)
JP (1) JP4212354B2 (de)
KR (1) KR100824134B1 (de)
CN (2) CN1280275C (de)
AR (1) AR035349A1 (de)
AT (1) ATE538096T1 (de)
AU (2) AU2002210524B2 (de)
BR (1) BRPI0114576B1 (de)
CA (1) CA2425268C (de)
CY (2) CY1112442T1 (de)
CZ (1) CZ304558B6 (de)
DK (2) DK1326841T3 (de)
ES (2) ES2378059T3 (de)
GB (1) GB0024808D0 (de)
GC (1) GC0000307A (de)
HU (1) HU230767B1 (de)
IL (2) IL155278A0 (de)
MX (1) MXPA03003176A (de)
MY (1) MY135766A (de)
NO (1) NO325107B1 (de)
NZ (1) NZ525225A (de)
PL (1) PL207560B1 (de)
PT (2) PT2258688E (de)
SI (2) SI1326841T1 (de)
TW (1) TWI293293B (de)
WO (1) WO2002030904A1 (de)
ZA (1) ZA200302785B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686119B1 (de) * 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1735457A4 (de) 2004-04-16 2007-08-29 Glaxo Group Ltd VERFAHREN ZUR BESTIMMUNG VON Lp-PLA2-AKTIVITÄT UND HEMMUNG VON Lp-PLA2 AKTIVITÄT
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
CN101986785A (zh) * 2007-05-11 2011-03-16 托马斯杰弗逊大学 治疗和预防神经退行性疾病和紊乱的方法
AU2008251467B2 (en) * 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
WO2011049722A1 (en) * 2009-10-19 2011-04-28 Merck Sharp & Dohme Corp. PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS
US20130211209A1 (en) 2010-06-18 2013-08-15 Majid Sarrafzadeh Energy aware sensor management for wearable medical systems optimization
PE20140421A1 (es) 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
CN103906744A (zh) 2011-09-01 2014-07-02 葛兰素集团有限公司 新晶型
EP2948452B1 (de) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Auf 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h-)-on basierende lipoprotein-assoziierte phospholipase-a2 (lp-pla2)-inhibitoren
BR112015017768A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN112510260B (zh) * 2020-11-27 2022-11-04 珠海市赛纬电子材料股份有限公司 电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5769527A (en) 1986-07-17 1998-06-23 Vari-Lite, Inc. Computer controlled lighting system with distributed control resources
US5585246A (en) 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
EP0658205B1 (de) 1993-06-25 2000-03-15 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
EP1096016B1 (de) 1993-10-06 2006-01-11 Icos Corporation Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CN1175246A (zh) 1994-12-22 1998-03-04 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的取代的氮杂环丁－2－酮
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
JP2002515852A (ja) 1995-07-01 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン誘導体
FR2743912B1 (fr) 1996-01-24 1998-04-10 Matra Communication Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en) 1996-01-25 1997-11-04 Hazeltine Corporation Validation of subscriber signals in a cellular radio network
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
IL130181A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (en) * 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
US6559155B1 (en) 1998-08-21 2003-05-06 Smithkline Beecham P.L.C. Pyrimidinone derivatives for the treatment of atherosclerosis
HUP0201122A3 (en) 1999-05-01 2003-11-28 Smithkline Beecham Plc Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CN1951917B (zh) 2012-07-18
IL155278A (en) 2015-05-31
CY1112442T1 (el) 2015-12-09
NO325107B1 (no) 2008-02-04
ES2378059T3 (es) 2012-04-04
DK1326841T3 (da) 2012-02-27
CY1113648T1 (el) 2016-06-22
HUP0302480A3 (en) 2010-03-29
JP2004512283A (ja) 2004-04-22
ES2399325T3 (es) 2013-03-27
ZA200302785B (en) 2004-07-09
CN1479724A (zh) 2004-03-03
KR100824134B1 (ko) 2008-04-21
CA2425268C (en) 2011-09-13
ATE538096T1 (de) 2012-01-15
AU1052402A (en) 2002-04-22
EP2258688B1 (de) 2012-11-21
HK1144941A1 (en) 2011-03-18
GC0000307A (en) 2006-11-01
HK1058036A1 (en) 2004-04-30
AU2002210524B2 (en) 2004-06-03
PL207560B1 (pl) 2011-01-31
NO20031626L (no) 2003-06-04
PT2258688E (pt) 2013-02-04
CA2425268A1 (en) 2002-04-18
EP1326841A1 (de) 2003-07-16
GB0024808D0 (en) 2000-11-22
CZ304558B6 (cs) 2014-07-09
DK2258688T3 (da) 2013-02-04
MXPA03003176A (es) 2003-07-14
NZ525225A (en) 2004-10-29
US20050014793A1 (en) 2005-01-20
BRPI0114576B1 (pt) 2017-05-30
TWI293293B (en) 2008-02-11
PT1326841E (pt) 2012-03-08
AR035349A1 (es) 2004-05-12
MY135766A (en) 2008-06-30
SI1326841T1 (sl) 2012-04-30
KR20030036916A (ko) 2003-05-09
PL366334A1 (en) 2005-01-24
US7235566B2 (en) 2007-06-26
SI2258688T1 (sl) 2013-03-29
CZ20031009A3 (cs) 2003-11-12
US20040063753A1 (en) 2004-04-01
JP4212354B2 (ja) 2009-01-21
NO20031626D0 (no) 2003-04-09
HUP0302480A2 (hu) 2003-12-29
BR0114576A (pt) 2004-07-27
HU230767B1 (hu) 2018-03-28
EP1326841B1 (de) 2011-12-21
CN1951917A (zh) 2007-04-25
WO2002030904A1 (en) 2002-04-18
CN1280275C (zh) 2006-10-18
EP2258688A1 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
IL155278A0 (en) Pyridinone derivatives for treatment of atherosclerosis
IL213240A0 (en) Method of treatment using lighnd-immunogen conjugates
GB0014969D0 (en) Novel method of treatment
SG86377A1 (en) Method of sterilization
PL342076A1 (en) Method of treating surfaces
AU2001286983A1 (en) Method of treatment
AU7845701A (en) Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
IL152810A0 (en) Novel polymorph v of torasemide
HUP0300703A3 (en) Process for the preparation of quinoline derivatives
GB2380481B (en) Means for treatment of atherosclerosis
GB0008921D0 (en) Method of treatment
HUP0301027A3 (en) Process for the extraction of 2-hydroxy pyridine 2-hydroxyquinoline and 2-hydroxybenzothiazole derivatives
EP1359912A4 (de) Neue verfahren zur anwendung von pyridinderivaten
EP1303281A4 (de) Verfahren zur behandlung
AU6789501A (en) Method of dusting-preventive treatment of powder having dusting property
PL343942A1 (en) Novel derivative of isothiazole pyridine
GB0002762D0 (en) Method of treatment
PL341634A1 (en) Method of obtaining derivatives of phenylsulphonylmethyltetrazole
HK1052861A (en) Vaccine for the treatment of atherosclerosis
GB0026742D0 (en) Novel method of treatment
AUPR213000A0 (en) Method of treatment
AUPQ662500A0 (en) Method of treatment
AUPQ949500A0 (en) Method of treatment
GB0013928D0 (en) Methods of treatment
GB0014904D0 (en) Methods of treatment